8-KOther Events

VERTEX PHARMACEUTICALS INC / MA 8-K Report (Feb 13, 2004)

Filed February 13, 2004For Securities:VRTX

Summary

This 8-K filing from Vertex Pharmaceuticals Inc. on February 13, 2004, reports on a significant debt refinancing transaction. Vertex successfully completed an exchange offer for its outstanding 5% Convertible Subordinated Notes due 2007. Approximately $153 million of these notes were exchanged for an equal principal amount of newly issued 5.75% Convertible Senior Subordinated Notes due 2011. This transaction represents a strategic move by Vertex to extend its debt maturity and increase its interest expense, likely to improve its capital structure and financial flexibility. Investors should note the change in coupon rate and the extension of the maturity date, which could impact the company's future interest payments and debt servicing obligations. The press release detailing this event is attached as an exhibit.

Key Highlights

  • 1Vertex Pharmaceuticals completed an exchange offer for its 5% Convertible Subordinated Notes due 2007.
  • 2Approximately $153 million in principal amount of the 2007 notes were exchanged.
  • 3New 5.75% Convertible Senior Subordinated Notes due 2011 were issued in exchange.
  • 4The exchange effectively extended the maturity of a significant portion of Vertex's convertible debt.
  • 5The new notes carry a higher interest rate of 5.75% compared to the previous 5%.
  • 6The press release announcing this transaction is filed as Exhibit 99.1.

Frequently Asked Questions

The primary purpose of the debt exchange was to refinance Vertex Pharmaceuticals' outstanding 5% Convertible Subordinated Notes due 2007. This move aimed to extend the maturity of the company's debt obligations and potentially enhance its financial flexibility.

The new notes are 5.75% Convertible Senior Subordinated Notes due 2011, replacing the 5% Convertible Subordinated Notes due 2007. Key changes include an increase in the annual interest rate from 5% to 5.75% and an extension of the maturity date from 2007 to 2011.

Approximately $153 million in aggregate principal amount of Vertex's 5% Convertible Subordinated Notes due 2007 were exchanged for an equal principal amount of the new 5.75% Convertible Senior Subordinated Notes due 2011.

According to the filing, the information is being furnished and shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings unless expressly stated.